Humira Biosimilar Settlement Could Be Model For Other Disputes

 
• By Brenda Sandburg

Agreement with AbbVie allows Amgen to launch its Humira biosimilar in Europe in 2018 and in the US in 2023; it may be akin to generic settlements but it is uncertain if other sponsors will get similar deals.

3D illustration of molecular structure and communication concept on dark background. science, connection, biology, medicine

More from Biosimilars

More from Biosimilars & Generics